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AbstrAct
Introduction The increasing burden of cancer morbidity 
and mortality has led to the development of national health 
initiatives to promote earlier cancer diagnosis and improve 
cancer survival. This protocol describes a systematic 
review aiming to identify the evidence about such 
initiatives among the adult population. We will describe 
their components, stakeholders and target populations, 
and summarise their outcomes.
Methods and analysis We will search databases and 
websites for peer-reviewed publications and grey literature 
on national health initiatives in high-income countries as 
defined by the World Bank. Quantitative, qualitative and 
mixed-methods studies will be included and assessed 
for their methodological quality. Study selection, quality 
assessment and data extraction will be carried out 
independently by two reviewers. Narrative synthesis will 
be used to analyse the findings.
Ethics and dissemination This systematic review 
analyses secondary data and ethical approval is not 
required. Review findings will be helpful to researchers, 
policy makers, governments and other key stakeholders 
developing similar initiatives and assessing cancer 
outcomes. The results will be submitted to a peer-
reviewed journal in order to reach a diverse group of 
healthcare professionals, researchers and policy makers. 
This systematic review protocol is registered at PROSPERO 
(CRD42016047233).
IntroductIon
Cancer imposes a significant public health 
burden worldwide; in 2012, there were over 
14 million diagnoses and 8.2 million cancer 
deaths.1 Cancer incidence has increased 
over time,2 partly due to population ageing 
and lifestyle factors such as diet, tobacco 
use, alcohol consumption, obesity and phys-
ical inactivity.3 In the UK, it is estimated that 
one in two people born after 1960 will be 
diagnosed with cancer at some time in their 
lives.4
Furthermore, the number of people 
surviving cancer is increasing, mainly as 
a result of improvements in early detec-
tion and treatment.5 6 In 2012, there were 
32.6 million 5-year cancer survivors world-
wide.7 There is, however, a wide survival gap 
between different countries.8 In Europe, 
England and Denmark have been identi-
fied as having poor survival rates compared 
with other Western European countries.5 9 
Late cancer stage at diagnosis and quality of 
treatment have been described as important 
explanatory factors for international varia-
tion in cancer survival.10–12
The increased burden of cancer and the 
opportunity to improve survival have driven 
the development of organised health system 
level initiatives related to early cancer detec-
tion. In 2002, the WHO recommended the 
development of national cancer control 
programmes adopting ‘strategies for preven-
tion, early detection, diagnosis, treatment, 
and palliation’ of cancer. Suggested early 
detection strategies included promoting the 
awareness of cancer signs and symptoms and 
training health professionals.13 Acknowl-
edging resource variation across countries, 
the WHO recommended the adoption and 
implementation of nationwide strategies in 
countries with high level of resources and 
community approaches in countries where 
resources are limited.13 In 2005, the WHO 
approved a resolution on Cancer Prevention 
and Control14; one of its recommendations 
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Protocol
Strengths and limitations of this study
 ► To our knowledge, there are no other studies 
systematically reviewing national cancer strategies 
promoting the earlier diagnosis of cancer and 
describing their characteristics, populations and 
overall outcomes.
 ► Limitations include challenges related to wide 
heterogeneity in the composition and intensity of 
initiatives, populations and contexts, and carrying 
out comprehensive literature searches in such a 
broad area.
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was to reduce late presentation for cancers that are 
amenable to early detection and treatment.15
In the UK, the National Awareness and Early Diag-
nosis Initiative (NAEDI) was launched in 2008, led by 
the Department of Health and Cancer Research UK (a 
leading cancer charity) with the aim of improving cancer 
outcomes.16 A similar initiative (the Detect Cancer Early 
Programme) was launched by the Scottish government 
in 2012, aiming to improve overall 5-year survival for 
patients with lung, breast and colorectal cancers.17 In 
Denmark, a novel strategy focusing on different path-
ways for patients presenting with a range of symptoms 
was established with the aim to expedite early diagnosis 
and treatment.18
These health initiatives are complex, with several inter-
acting components19 and often require behaviour change 
from their target population. Furthermore, they may 
focus on different groups or organisational levels and can 
change depending on the context.19 Synthesising results 
of such initiatives in a systematic way is methodologi-
cally challenging, from defining the research questions 
to discussing the applicability of findings.20 Nonetheless, 
efforts should be made to review the evidence in order to 
inform and enhance future initiatives aiming to promote 
early cancer diagnosis and influence cancer survival. 
Reporting on their activities and outputs is also important 
to enhance transparency and accountability, especially 
when these initiatives are directly or indirectly funded by 
the public.21
Previous reviews have attempted to summarise the 
evidence on national health initiatives in promoting the 
early diagnosis of cancer. González-Robledo et al carried 
out a database and documentary analysis of Latin Amer-
ican governmental actions for early detection of breast 
cancer and described how these often operated through 
regulation, design and implementation of early diagnosis 
programmes, care provided by public and private services 
and the development of guidelines for early detection.22 
Palmer’s overview of different UK cancer policies cited 
a few government interventions aiming to promote the 
earlier diagnosis of cancer and described factors associ-
ated with poor cancer survival, including socioeconomic 
deprivation.23 Brown and colleagues investigated how 
different healthcare system characteristics (several regions 
in six countries were investigated) could contribute 
towards a number of cancer outcomes, including early 
diagnosis. The authors acknowledged that identifying 
causal relationships between healthcare system character-
istics and cancer outcomes was challenging in complex, 
context-specific systems.24
To our knowledge, there are no existing systematic 
reviews summarising national cancer initiatives at a 
health system-level worldwide, describing their charac-
teristics, populations and overall outcomes. This review 
will add to existing knowledge into the area, systemati-
cally reviewing the international literature on national 
cancer initiatives promoting the earlier diagnosis of 
cancer.
Methods and analysIs
This protocol describes a systematic review that is investi-
gating health system level initiatives promoting the earlier 
diagnosis of cancer. We are guided by the Preferred 
Reporting Items for Systematic Reviews and Meta-Anal-
yses (PRISMA) P-checklist,25 the PRISMA guidelines for 
reporting systematic reviews,26 the Cochrane Handbook 
for Systematic Reviews of Interventions27 and the Centre 
for Reviews and Dissemination’s guidance for under-
taking systematic reviews28 when developing this protocol. 
Guidance on reviewing complex interventions has also 
been consulted.19 29
study objectives
The review seeks to identify, describe and categorise 
the available evidence on national initiatives aiming to 
promote early diagnosis of cancer among the adult popu-
lation. Our review methodology was developed in order 
to answer the following broad research questions:
1. What are the key components of these initiatives?
2. Who are the target populations and what are their 
sociodemographic characteristics?
3. What are the reported overall outcomes of these 
initiatives?
4. Where reported, what are the perspectives of 
participants (patients, professionals and policy 
makers) on these multilevel cancer initiatives?
If available in the included studies, we will also explore 
relevant contextual issues or any barriers/facilitators that 
may help to shed light on how/why the initiatives’ speci-
fied objectives were (or not) achieved.
study selection criteria
Study selection criteria are described in text and 
summarised in table 1.
study designs and publication types
We will include experimental and non-experimental 
(observational) study designs. Quantitative, qualitative 
and mixed-methods studies are eligible for inclusion.
Study protocols, reviews/overviews, editorials, 
commentaries, short reports, viewpoints and letters to 
the editor are eligible for inclusion as these publications 
can provide important information on the components 
of national initiatives and their target populations (in 
addition to contextual information). Theses, government 
reports and other official documents are also eligible for 
inclusion.
Conference abstracts are eligible for inclusion provided 
that full-text about the initiative is also identified. 
Reviews/overviews are eligible for inclusion if they report 
on data from a single multilevel initiative (eg, describing 
its different components/programmes). Those reporting 
on more than one initiative will be excluded, but their 
references will be checked in order to identify additional 
eligible studies. Published guidelines from professional 
bodies that are not part of a government initiative will be 
excluded.
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Table 1 Inclusion and exclusion criteria
Inclusion criteria Exclusion criteria
Design and publication types
 ►Experimental and non-experimental studies
 ►Studies using quantitative, qualitative or mixed methods
 ►Protocols, editorials, commentaries, short reports, 
viewpoints and letters to the editor
 ►Reviews/overviews and systematic reviews reporting on 
a number of components from a single national strategy/
initiative
 ►Conference abstracts when full-text about initiatives is 
also available
 ►Reviews and systematic reviews reporting on more than one 
national initiative
 ►Conference abstracts when full-text about initiatives is not 
available
 ►Published guidelines/recommendations from professional 
bodies that are not part of a government initiative
 ►Publications without full-text in English
Population and setting
 ►Adults (aged 18 years or older)
 ►Patients/member of the public with or without medical 
conditions
 ►Healthcare professionals
 ►Health institutions/settings
 ►High-income countries (World Bank)
 ►Children (aged 17 years or younger)
 ►Professionals working in an administrative capacity (even if 
within a health system)
 ►Low-income and middle-income countries (World Bank)
Interventions
 ► Initiatives aiming to promote early diagnosis
 ► Initiatives addressing the patient/member of the public 
and at least two more levels of contextual influence (see 
Taplin et al)
 ►National level initiatives or equivalent (ie, state or 
provincial level depending on health system structure and 
autonomy)
 ► Initiatives aiming to support the entire cancer trajectory or to 
reduce cancer disparities (in which early diagnosis is only a 
component)
 ► Initiatives focusing on primary prevention, surveillance 
programmes, genetic counselling, cancer recurrence or 
screening programmes
 ►Cost-effectiveness studies
 ► Initiatives addressing the patient/public only
 ►Small, localised research studies and purely academic 
research studies/projects
Comparators and outcomes
 ►Any comparators (studies without comparators are also 
eligible for inclusion)
 ►High-level outcomes (national or equivalent) related to 
the initiatives’ main aims (eg, improve awareness and 
diagnose cancer earlier)
 ►Overall views/experiences about initiatives
 ►Local, setting-specific outcomes
 ►Outcomes for a single cancer type (when strategies targeted 
more than one type)
study population and setting
Initiatives aiming to promote earlier cancer diagnosis 
for the adult population (aged 18 years and over) will be 
included due to their relevance regarding the increased 
burden of cancer incidence and mortality. Initiatives 
aiming to promote earlier cancer diagnosis for any cancer 
types are eligible for inclusion. Health status will not be a 
reason for exclusion; we are interested in early diagnosis 
initiatives aiming at healthy participants or patients with 
any underlying medical conditions (provided that the 
focus is not on these other conditions).
Initiatives may also involve interventions with health-
care professionals. Hence, interventions targetted at 
general practitioners, other medical doctors, nurses and 
any allied professionals (such as pharmacists and radiog-
raphers) are eligible for inclusion. Initiatives carried out 
solely with professionals working on an administrative 
capacity (such as practice managers and hospital admin-
istrators) will be excluded. Finally, initiatives may also 
have healthcare providers, institutions and governments 
in receipt of an intervention. These groups are therefore 
also eligible for inclusion.
Initiatives carried out in high-income countries as 
classified by the World Bank30 are eligible for inclusion. 
Low-income and middle-income countries are being 
excluded due to the diversity of health systems, popula-
tions and challenges (which would impair the ability to 
compare review results with activities from the Detect 
Cancer Early Programme in Scotland—as part of a large 
study of which this review is a component).
Interventions
We will include national initiatives/strategies with the 
explicit aim to promote earlier cancer diagnosis at a 
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health system level. Healthcare delivery occurs in a 
multilevel system, where multiple levels of contextual 
influence may affect behaviour.31 Taplin et al describe 
seven different levels: (1) the individual patient, (2) 
family and social supports, (3) provider/team, (4) organ-
isation and/or practice setting, (5) local community 
environment, (6) state health policy environment and/
or (7) national health policy environment. The authors 
stipulate that multilevel interventions should address the 
patient (individual level) in addition to at least two more 
levels.31 All included studies will be required to meet 
this requirement, although adaptations are possible (eg, 
a member of the general public may also represent the 
individual level, and not all countries may have a state 
level). Interventions will be required to have involvement 
from governments (at state or national level), although 
non-governmental organisations may also be involved. 
Small, localised research studies within a single hospital/
other institution and purely academic research studies 
are not considered a national initiative and will there-
fore be excluded. Importantly, we are adopting Taplin 
et al’s definition of interventions, that is, any ‘specified 
strategy or set of strategies designed to change the knowl-
edge, perceptions, skills, and/or behaviour of individuals, 
groups, or organisations, with the aim of improving 
patients’ health outcomes’.31 Hence, interventions may 
refer to trials or observational studies (including natural 
experiments).
Possible interventions aiming to promote earlier 
cancer diagnosis include but are not limited to campaigns 
to increase knowledge/awareness of cancer, training 
for healthcare professionals and development of care 
pathways to cancer diagnosis and treatment. We are 
particularly interested in initiatives that (1) raise aware-
ness of symptoms and encourage prompt presentation 
by patients; and (2) facilitate timely investigation and 
referral in primary care. Initiatives focusing solely on 
primary cancer prevention such as those targeting life-
style changes, reduction of exposure to environmental 
factors that may cause cancer or vaccinations (ie, against 
human papillomavirus), surveillance programmes for 
patients with Helicobacter pylori (a risk factor for stomach 
cancer) or Barrett’s oesophagus (a risk factor for oesoph-
ageal cancer) will be excluded. Studies focusing on 
patients with genetic susceptibility of cancer, aiming to 
avoid cancer recurrence or cost effectiveness studies will 
also be excluded. Likewise, publications solely describing 
cancer screening programmes will be excluded (as these 
refer to a different, vast body of literature).
comparators
Due to our broad aim, the diverse nature of the initiatives 
and the inclusion of quantitative and qualitative studies, 
it is likely many included studies will not have comparator 
populations. When these are present, they are likely to 
include: (1) indicators before (baseline) and after (one 
or more time points) at an individual and group level; or 
at the provider, organisation, local community, state and 
national levels; or (2) those in receipt versus those either 
not in receipt of any initiative or in receipt of a different 
initiative.
outcomes
This review aims to provide an overview of different 
initiatives as opposed to systematically assess all available 
outcomes for each identified initiative, as this would 
require a number of different reviews. We will only report 
overall, high-level outcomes (as the review’s aim is to 
identify, describe and categorise national health initia-
tives without focusing on the outcomes). The review will 
summarise key features, target populations and reported 
measures used to monitor and evaluate different strate-
gies. Local, setting-specific outcomes described in small 
studies about different initiatives will therefore not be 
reported. We will identify core publications for each 
initiative (from which data will be extracted) and list all 
other relevant, additional publications identified in the 
searches (categorising them according to the strategies 
they are referring to). We expect that the search strategy 
will identify a number of such additional publications.
High-level quantitative outcomes may include but 
are not limited to measures of knowledge/awareness 
of cancer, cancer symptoms or cancer screening; proxy 
measures of survival such as cancer stage at diagnosis may 
also be available.
Qualitative outcomes of interest include any views or 
experiences from professionals regarding the initiatives 
that may shed light on issues regarding implementation, 
feasibility and acceptability of initiatives. Patients and the 
public may provide perspectives on the impact of the 
initiatives and the importance of outcomes.19 Findings 
from qualitative studies may also help to shed light on the 
context (geographical, cultural, social, organisational or 
political) in which initiatives were implemented.19
Some studies may be reporting ongoing interventions 
and data on health outcomes may not yet be available. 
It is also possible that some eligible publications will 
be descriptive in nature, presenting an overview of 
programmes.
search strategy
A search strategy has been developed by the authors by 
making a list of keywords considered to be relevant based 
on the authors’ knowledge of available literature on 
cancer and early diagnosis and looking at search strate-
gies from specific publications in the area.32 33 The search 
strategy was then refined after discussions with a senior 
academic liaison librarian experienced with developing 
systematic review protocols in the field of health sciences. 
The search strategy was tested to ensure it was identifying 
relevant publications. It is broad as it was challenging to 
define specific keywords based on the research questions, 
and there was the possibility of missing too many relevant 
studies. It is also likely that national health initiatives are 
not described as such even when this is the case. We are 
therefore prioritising sensitivity over precision27 in order 
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Table 2 MEDLINE search strategy*
1 government or policy$ or policies or national or regional or multi-level$ or system-level or whole-system$ or NAEDI 
or ‘Detect Cancer Early’ or ‘National Awareness and Early Diagnosis Initiative’ or ‘Find Cancer Early’ or ‘Be Cancer 
Aware’ or ‘Be Clear on Cancer’ or initiative$ or program$ or campaign$ or strateg$ or engagement or awareness.mp
2 health$ adj2 (care or service$ or system$ or seek$ or provi$).mp
3 surviv$.mp
4 delay$ adj4 (diagnos$ or present$ or treat$ or consult$ or patient$ or doctor$ or system$ or refer$ or therap$ or care 
or detect$).mp
5 time adj4 (diagnos$ or present$ or treat$ or refer$ or care or detect$).mp
6 late adj4 (diagnos$ or treat$ or refer$ or present$ or detect$).mp
7 earl$ adj4 (diagnos$ or present$ or treat$ or refer$ or therap$ or detect$).mp
8 3 or 4 or 5 or 6 or 7
9 Cancer$ or neoplas$ or tumour or tumor or malign$ or oncolog$.mp
10 Randomi$ or RCT or intervention or trial or cross-sectional or survey$ or questionnaire$ or train$ or ‘natural 
experiment’ or interview$ or ‘focus group$’ or ‘case study’ or observation$ or time-series or ‘time series’ or CBA 
or ‘controlled before and after’ or ‘controlled before-after’ or prospective or retrospective or cohort or case-control 
or cross-over or ‘case series’ or case-reports or ‘case reports’ or feasibility or pilot or narrative or qualitative or 
quantitative or mixed-methods or ‘mixed methods’ or evaluat$ or assess$ or attitude$ or view$ or perception$ 
or perspective$ or ‘discourse analysis’ or ‘content analysis’ or ‘thematic analysis’ or ‘narrative analysis’ or 
phenomenolog$ or ‘purposive sampl$’ or ethnograph$ or ‘theoretical sampl$’ or ‘grounded theory’.mp
11 1 and 2 and 8 and 9 and 10
12 11 not (child$ or pediatric$ or paediatric$ or adolesc$ or teenag$).ti
13 12 not (palliative or terminal or ‘end of life’ or end-of-life or ‘advance directive$’ or hospice$).ti
14 13 not (biomarker$ or molecul$).ti.
15 limit 14 to (english language and humans and yr=‘2005 -Current’)
*‘.mp’ searches automatically for subject heading (MeSH) fields.
not to miss important eligible studies. This is especially 
important when including qualitative studies.32 Syntaxes/
Boolean operators will be changed to meet the require-
ments of different research platforms. The MEDLINE 
search strategy is shown in table 2.
A number of databases (such as EMBASE, PsycInfo, 
MEDLINE and ASSIA; table 3) will be searched elec-
tronically, including those focusing on grey literature. 
Government and charity websites will be searched in 
addition to different data repositories for randomised 
controlled trials and studies funded by the European 
Commission.
We will check the reference lists of all included studies. 
If relevant references are not available online, we will 
contact the authors to request these. Finally, the list of 
included studies will be checked by all authors to verify 
whether any relevant studies known to them are missing.
We will include all studies published from 2005 onwards. 
This cut-off point was chosen as this was the year that the 
WHO approved its resolution on Cancer Prevention and 
Control.15 Broader inclusion criteria will allow for the 
identification of less well-known initiatives worldwide, 
with diverse health contexts (such as universal health 
coverage) and approaching different populations (such 
as deprived groups, those living in rural areas and ethnic 
minorities). Due to resource limitations, only publica-
tions in English will be included. Initially, we envisioned 
to include publications in Spanish and Portuguese (as 
we have the resources to translate these), but we were 
concerned that the results would then be biased towards 
initiatives in countries where these languages are spoken. 
We do acknowledge, however, that publications will be 
biased towards studies published in English (implications 
will be discussed). Full-text publications in any language 
other than English will be excluded even if the abstracts 
are available in this language. We will prepare a descrip-
tive supplementary table listing these potentially eligible 
abstracts that only had full-text in a different language.
data management, selection and extraction
Citations and abstracts from searches will be exported 
into EndNote X7 for Windows. After removing duplicates, 
the studies will be screened using a multistep procedure. 
First, one author will screen all the titles and abstracts 
against the inclusion criteria. Another author will screen 
a random selection (30%) of the excluded studies at 
this step. Second, two review authors will independently 
screen the full-text of reports in order to select papers 
for inclusion. Finally, the two authors will carefully reas-
sess the full-text of all included articles (independently) 
in order to ensure they have relevant information which 
could be extracted. Articles that do not have this will be 
excluded from the analysis. The study selection process 
will be recorded in SPSS version 22 for Windows. A 
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Table 3 Electronic data sources
Search platform/provider Databases
Cochrane Library (single search)  ►Cochrane Database of Systematic Reviews (CDSR)
 ►Cochrane Central Register of Controlled Trials (CENTRAL)
 ►Database of Abstracts of Reviews of Effects (DARE)
 ►Health Technology Assessment Database (HTA)
 ►NHS Economic Evaluation Database (EED)
Ovid (searching each database 
independently)
 ►Embase Classic + Embase
 ►MEDLINE(R) and MEDLINE(R) In-Process & Other Non-Indexed Citations
 ►PsycInfo
 ►PsycARTICLES full-text
Web of Science Core Collection 
(single search)
 ►Scielo
 ►Science and Social Sciences
 ►Conference Proceedings in Science and Social Science & Humanities
ProQuest (single search)  ►ProQuest Dissertations & Theses Global
 ►Applied Social Sciences Index and Abstracts (ASSIA)
 ► International Bibliography of the Social Sciences (IBSS)
 ►PAIS International
EBSCOhost (single search)  ►Cinahl Plus
 ►SocINDEX with full-text
Other sources of data  ►United Kingdom: UK Department of Health Publications and Statistics; The 
Knowledge Network (NHS e-library); UK Clinical Research Network; Healthcare 
Management Information Consortium (HMIC) database
 ►United States: Centers for Disease Control and Prevention
 ► International Agency for Research on Cancer
 ►European Commission’s Community Research and Development Information Service 
(CORDIS)
 ►OECD iLibrary
 ►Charities worldwide: Cancer Research UK, Marie Curie, Macmillan Cancer Support, 
The King’s Fund, The Nuffield Trust, National Cancer Research Institute, World Cancer 
Research Fund International, American Lung Association, American Cancer Society, 
Cancer Research Institute, National Cancer Institute, Cancer Council Australia, 
Canadian Cancer Society, Danish Cancer Society, Cancer Society of New Zealand, 
German Cancer Aid, Irish Cancer Society, Dutch Cancer Society, Norwegian Cancer 
Society, Portuguese Cancer League, Asociación Española Contra el Cáncer, Swedish 
Cancer Society, Nordic Cancer Union, German Cancer Society
 ►Theses: EThOS - Electronic Theses Online Service; Dart-Europe
 ►Clinical Trials: U.S. National Institutes of Health’s Clinical Trials Database; WHO 
International Clinical Trials Registry Platform Search Portal; UK Clinical Trials Gateway
 ►Grey literature: Open Sigle
PRISMA flow diagram26 will be developed. Study authors 
will be contacted if additional information is required to 
decide eligibility. One reminder will be sent if there are 
no replies. All disagreements at each step will be solved 
by consensus; a third review author will be consulted if 
consensus cannot be obtained.
A data extraction template has been created in Micro-
soft Word for Windows (see online supplementary file 
S1). It includes contextual information on the initiatives 
and a description of its key components, in addition to 
information on study design, setting, location, other 
characteristics of the intervention, of study participants 
and outcomes. Two reviewers will independently extract 
data from three randomly selected included studies and 
compare their forms in order to reduce bias and ensure 
the forms are being used in a similar manner. After-
wards, one reviewer will extract data from 50% of the 
included studies and another will extract data from the 
remaining 50%. The two researchers will compare form 
content and discuss any disagreements. A third reviewer 
will be consulted if disagreements cannot be solved by 
consensus. Extracted data will be described in text, tables 
and diagrams.
Quality assessment
We anticipate that the included studies will be varied 
in terms of study design and that most will be observa-
tional studies.34 This leads to challenges in choosing a 
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quality assessment tool that can be used appropriately for 
different designs. We will therefore use more than one 
assessment tool.
Quantitative studies will be analysed using the McMaster 
Critical Review Form for Quantitative Studies,35 available 
in online supplementary file S2. This tool is suitable for 
different types of quantitative studies (cross-sectional, 
cohort, case–control, among many others). It contains 
multiple choice questions regarding the study purpose, 
literature, design, sample, outcomes, intervention, results, 
conclusions and implications. The tool also approaches 
issue of bias, validity and reliability. Percentage agree-
ment between two researchers has been assessed (from 
75% to 86%) and guidance on how to assess studies is also 
provided.35
Qualitative studies will be assessed using the quality 
assessment tool from Hawker and colleagues,36 which 
was developed to evaluate the quality of heterogeneous 
studies in systematic reviews. The original tool has nine 
items and allows for four possible answer options (‘good’, 
‘fair’, ‘poor’ and ‘very poor’). Item six will be divided 
into two different items in order to separately assess issues 
related to ethics and bias as these are shown together 
in the original instrument (adapted tool is available in 
online supplementary file S3). This adaptation has been 
successfully done in a previous systematic review assessing 
qualitative studies.37 Study protocols, editorials, commen-
taries, short reports and viewpoints will also be assessed 
using this tool (limitations will be acknowledged).
Letters to the editor, conference abstracts and grey 
literature such as government reports/cancer strategies 
will not be assessed for quality; potential methodolog-
ical issues and risks of bias will be discussed. Reviews 
and systematic reviews will be assessed using the vali-
dated Oxman and Guyatt’s 10-item checklist (Overview 
Quality Assessment Questionnaire), as this tool is suitable 
for both systematic and non-systematic reviews38 39 (see 
online supplementary file S4).
Mixed-methods studies will be assessed using both the 
tools for qualitative and quantitative studies; results for 
both assessments will be reported. For all studies we will 
report each quality component separately in a supplemen-
tary table due to recognised problems with calculating 
single summed quality scores.40 41
Each study will be independently assessed by two 
reviewers, with disagreements solved by consensus. A 
third reviewer will be consulted if no consensus can be 
reached. We will report the % agreement and kappa 
scores using the Landis and Koch guidelines.42
data synthesis
We expect wide heterogeneity in the composition and 
intensity of initiatives, populations and contexts29 43 
and predict that meta-analysis will not be possible nor 
appropriate considering the review aims. We will carry 
out narrative synthesis; this is a widely used method 
when there is heterogeneity.28 43 Narrative synthesis is 
an approach that relies on using words and text to ‘tell 
a story’ of findings.44 It is useful in reviews investigating 
questions that are not solely focused on the effectiveness 
of interventions43 and well suited for complex interven-
tions.19 Narrative synthesis has also been described as 
particularly effective to synthesise qualitative and quan-
titative evidence45 and to make explicit different study 
designs and contexts.46 We will follow published guide-
lines for using this method44 and take into account 
reported limitations of this approach.47
Data will be reported irrespective of the results from the 
quality assessment; implications will be discussed. Find-
ings will be described in text and in tables and categorised 
in line with Taplin et al’s refined model of multilevel influ-
ences on the cancer care continuum.31 We will provide 
details of key features of initiatives such as contextual 
issues (eg, described policies and source of funding), 
key components (such as relevant guidelines for refer-
ring patients to specialist services), target populations 
and timelines. When reporting outcomes we will take 
into account the updated NAEDI’s hypothesis of factors 
influencing cancer survival and premature mortality.11 
If feasible, a diagram will be created to summarise these 
results.
ethIcs and dIsseMInatIon
This systematic review protocol did not require ethical 
approval as there is no direct contact with research 
participants. There are also no issues of confidentiality 
or potential harms. Only secondary data from published 
studies and grey literature will be analysed.
The review results will be submitted to a peer-reviewed 
journal in early 2018 in order to reach a diverse group of 
healthcare professionals, researchers and policy makers.
dIscussIon
To our knowledge, this is the first systematic review 
aiming to describe the full breadth of national health 
initiatives in promoting earlier diagnosis of cancer in 
high-income countries, exploring their main character-
istics (such as key components and target populations) 
and describing available high-level outcomes. This is 
an important research area considering the burden of 
cancer worldwide and the predicted increased number of 
cancer cases, especially in the context of an ageing popu-
lation. Furthermore, as health systems, governments and 
other stakeholders invest in, and develop programmes to 
tackle the issue, it is paramount that evidence on similar 
initiatives is made available. This review will provide a 
more nuanced understanding of the components of such 
initiatives.
There are challenges to be faced due to the likely 
complexity of the included interventions, populations 
and health systems. Furthermore, carrying out compre-
hensive literature searches in such a broad knowledge 
area will be time-consuming. We are following several 
available guidelines and developing strategies to deal with 
these challenges.
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In conclusion, this review addresses a relevant, timely 
health issue that affects a large proportion of the 
worldwide population. The findings will be helpful to 
researchers, policy makers, government departments and 
key cancer charities developing similar initiatives and 
assessing cancer outcomes.
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